Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone.

BMC Cancer · 2015 · PMC4659203 · PMID 26603423

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

Evaluation of surrogate endpoints Prentice’s criterion one The 5-year OS rate was 72 % in the CCRT group and 84 % in the NACT+CCRT group, with a marginally significant difference ( P log-rank = 0.050; Fig. 1 ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.